Discover FDA-approved POTELIGEO (mogamulizumab-kpkc) for mycosis fungoides (MF) and Sézary syndrome (SS), two types of cutaneous T-cell lymphoma (CTCL).

Looking for more information on POTELIGEO, a FDA-approved type of IV infusion therapy? See responses to the most frequently asked questions.

Join us for our virtual Poteligeo Partners educational event to learn more about these two common subtypes of cutaneous T-cell lymphoma and ways to take control of your disease. Wed, November 13th, 2024 7:00 PM -- 8:00 PM ET

What is the most important information I should know about POTELIGEO? POTELIGEO may cause serious side effects that can be severe or life-threatening including skin problems, infusion reactions, infections, autoimmune problems, and complications from stem cell transplant.

Join us for our virtual Poteligeo Partners educational event to learn more about these two common subtypes of cutaneous T-cell lymphoma and ways to take control of your disease. Wed, November 13th, 2024 7:00 PM -- 8:00 PM ET

The most common side effects of POTELIGEO include rash, tiredness, diarrhea, muscle and bone pain, and upper respiratory tract infection. Before starting POTELIGEO treatment, tell your doctor about all your medical conditions, including whether you:

Interested in reading about the benefits of POTELIGEO, a form of immunotherapy? Explore the results of the POTELIGEO clinical trial.

POTELIGEO is a medicine your doctor can prescribe for adults with MF or SS who have tried at least 1 prior medicine (taken by mouth or injection) that did not work or in whom the disease has come back after treatment

Before starting POTELIGEO treatment, tell your doctor about all your medical conditions, including whether you: have had a severe skin reaction after receiving POTELIGEO

POTELIGEO may cause serious side effects that can be severe or life-threatening including skin problems, infusion reactions, infections, autoimmune problems, and complications from stem cell transplant.